search
Back to results

Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT

Primary Purpose

Supraventricular Tachycardia

Status
Completed
Phase
Phase 4
Locations
Singapore
Study Type
Interventional
Intervention
Calcium Channel Blocker & Adenosine
Sponsored by
Singapore General Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Supraventricular Tachycardia focused on measuring Supraventricular Tachycardia, Calcium Channel Blockers, Verapamil, Diltiazem, Adenosine

Eligibility Criteria

10 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • More than 10 years old
  • Electrocardiographic diagnosis of SVT
  • SVT not converted by the vagal manoeuvres

Exclusion Criteria:

  • Signs of impaired cerebral perfusion
  • Signs of pulmonary oedema
  • Subsequent diagnosis of other types of arrythmias rather than SVT
  • pregnancy by history

Sites / Locations

  • Singapore General Hospital

Outcomes

Primary Outcome Measures

Conversion to the sinus rhythm.

Secondary Outcome Measures

Recurrence of SVT
Stability of vital signs

Full Information

First Posted
December 19, 2006
Last Updated
February 9, 2017
Sponsor
Singapore General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00413712
Brief Title
Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT
Official Title
Comparism Between Efficacy and Effectiveness Between Slow Infusion of Calcium Channel Blockers and Intravenous Bolus Adenosine in the Management of Supraventricular Tachycardia in the Emergency Department.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
January 1997 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2001 (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Singapore General Hospital

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine the efficacy and effectiveness of calcium channel blockers and adenosine in the treatment of Supraventricular Tachycardia.
Detailed Description
Paroxysmal Supraventricular Tachycardia (SVT) is a common cardiac emergency encountered in the Emergency Department. Both Calcium Channel Blockers (CCB) and Adenosine have been using in the Management of SVT. Objective This study compared the efficacy and effectiveness between slow Infusion of Calcium Channel Blockers (either Verapamil or Diltiazem) and bolus intravenous Adenosine in termination of SVT. Methodology This was a prospective, randomised, controlled clinical trial comparing the efficacy and effects of intravenous adenosine with slow infusion of calcium channel blockers (verapamil or diltiazem) in patients presenting with SVT to an Emergency Department. The study was approved by the hospital's Ethics Committee. Patients of at least 10 years of age, who presented to the Emergency Department of the Singapore General Hospital with regular narrow complex tachycardia and an electrocardiographic(ECG) diagnosis of SVT that was not converted by vagal manoeuvres (Valsava manoeuvre or carotid sinus massage or both) and who were in SVT at the time of doctor attendance were included in the study. The exclusion criteria were as follows: Patients with signs of impaired cerebral perfusion (e.g. altered mental state) or acute pulmonary oedema Patients with a subsequent diagnosis of arrhythmias other than SVT (i.e. sinus tachycardia, atrial flutter, atrial fibrillation or idiopathic ventricular tachycardia) were excluded from the analysis if they were initially enrolled Pregnancy by history (urine pregnancy testing was not used to actively exclude the condition in any of the female patients entered into the study). Having selected the patients according to the criteria, they were randomly assigned into two groups: one to receive calcium channel blockers and the other, Adenosine. Within the former group, some were assigned randomly to receive Diltiazem and some to Verapamil. Diltiazem was given at the dose of 2.5mg per minute (4ml per minute of a concentration of 0.625 mg/ml) up to a maximum of 50 mg. The dose of Verapamil was 1mg per minute (4ml per minute of a concentration of 0.25mg/ml) up to a maximum of 20mg. Both were given as a slow intravenous infusion using a Terumo infusion pump. During intravenous infusion, the patient's vital signs, viz. heart rate and systolic and diastolic blood pressures, were monitored at two-minute intervals up to completion of infusion or conversion from SVT, whichever was the earlier. At the time of conversion to sinus rhythm, the infusion was stopped and the amount of drug infused was noted and recorded. Regarding the Adenosine group, all the patients were administered Adenosine as a rapid bolus within 2 sec through an 18G IV cannula at an antecubital vein, followed by 10 ml saline flush and elevation of the limb. Initially 6ml bolus was given rapidly, and if there was no conversion of the SVT within 2 min, another 12 mg bolus was administered. If SVT was not converted at the end of any of calcium channel blocker infusion, those patients were then given intravenous Adenosine as described above. Similarly, those patients who remained in SVT after first two initial boluses of Adenosine were again randomized to receive either Verapamil or Diltiazem. This allowed four orders of treatment as follows: Verapamil infusion followed by Adenosine Diltiazem infusion followed by Adenosine Adenosine followed by Verapamil infusion Adenosine followed by Diltiazem infusion If the tachycardia was not converted at the end of the study protocol, patients were managed either with synchronised electrical cardioversion if haemodynamically unstable or with further pharmacotherapy at the discretion of the treating physician if vital signs were stable. Following the successful conversion, patients' vital signs were closely monitored at 1 min (immediate post-conversion), 5,10, 15 min and finally 30 min of post-conversion. If they remained stable, they were shifted to observation ward with continuous telemetric monitoring. They were eventually discharged if there were no recurrence during the period of observation and arranged a follow-up appointment at Arrhythmia Clinic one week later. Patients with the recurrence of SVT during the two-hour observation period were managed at the discretion of the treating physician. Study end points were as follows: Conversion to sinus rhythm Withdrawal because of major adverse effects Completion of trial protocol without termination of tachycardia Data on the final analysis was obtained from follow-up records of Cardiology department as well. The cost of medication used for each patient was also computed to understand the cost aspects of different regimens.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Supraventricular Tachycardia
Keywords
Supraventricular Tachycardia, Calcium Channel Blockers, Verapamil, Diltiazem, Adenosine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
206 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Calcium Channel Blocker & Adenosine
Primary Outcome Measure Information:
Title
Conversion to the sinus rhythm.
Secondary Outcome Measure Information:
Title
Recurrence of SVT
Title
Stability of vital signs

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: More than 10 years old Electrocardiographic diagnosis of SVT SVT not converted by the vagal manoeuvres Exclusion Criteria: Signs of impaired cerebral perfusion Signs of pulmonary oedema Subsequent diagnosis of other types of arrythmias rather than SVT pregnancy by history
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lim S Han, MBBS,FRCS
Organizational Affiliation
Department of Emergency Medicine, Singapore General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Singapore General Hospital
City
Singapore
ZIP/Postal Code
62223322
Country
Singapore

12. IPD Sharing Statement

Citations:
PubMed Identifier
11841884
Citation
Lim SH, Anantharaman V, Teo WS. Slow-infusion of calcium channel blockers in the emergency management of supraventricular tachycardia. Resuscitation. 2002 Feb;52(2):167-74. doi: 10.1016/s0300-9572(01)00459-2.
Results Reference
background
PubMed Identifier
8727628
Citation
Brady WJ Jr, DeBehnke DJ, Wickman LL, Lindbeck G. Treatment of out-of-hospital supraventricular tachycardia: adenosine vs verapamil. Acad Emerg Med. 1996 Jun;3(6):574-85. doi: 10.1111/j.1553-2712.1996.tb03467.x.
Results Reference
background
PubMed Identifier
7741343
Citation
Madsen CD, Pointer JE, Lynch TG. A comparison of adenosine and verapamil for the treatment of supraventricular tachycardia in the prehospital setting. Ann Emerg Med. 1995 May;25(5):649-55. doi: 10.1016/s0196-0644(95)70179-6.
Results Reference
background
PubMed Identifier
7821934
Citation
Sethi KK, Singh B, Kalra GS, Arora R, Khalilullah M. Comparative clinical and electrophysiologic effects of adenosine and verapamil on termination of paroxysmal supraventricular tachycardia. Indian Heart J. 1994 May-Jun;46(3):141-4.
Results Reference
background
PubMed Identifier
2193494
Citation
Viskin S, Belhassen B. Acute management of paroxysmal atrioventricular junctional reentrant supraventricular tachycardia: pharmacologic strategies. Am Heart J. 1990 Jul;120(1):180-8. doi: 10.1016/0002-8703(90)90176-x.
Results Reference
background
PubMed Identifier
1944450
Citation
Camm AJ, Garratt CJ. Adenosine and supraventricular tachycardia. N Engl J Med. 1991 Dec 5;325(23):1621-9. doi: 10.1056/NEJM199112053252306. No abstract available.
Results Reference
background
PubMed Identifier
2064090
Citation
Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1991 Jul;20(7):717-21. doi: 10.1016/s0196-0644(05)80829-7.
Results Reference
background
PubMed Identifier
2193560
Citation
DiMarco JP, Miles W, Akhtar M, Milstein S, Sharma AD, Platia E, McGovern B, Scheinman MM, Govier WC. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med. 1990 Jul 15;113(2):104-10. doi: 10.7326/0003-4819-113-2-104. Erratum In: Ann Intern Med 1990 Dec 15;113(12):996.
Results Reference
background
PubMed Identifier
2664879
Citation
Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis. 1989 Jul-Aug;32(1):73-97. doi: 10.1016/0033-0620(89)90015-7. No abstract available.
Results Reference
background
PubMed Identifier
2589197
Citation
Garratt C, Linker N, Griffith M, Ward D, Camm AJ. Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia. Am J Cardiol. 1989 Dec 1;64(19):1310-6. doi: 10.1016/0002-9149(89)90573-0.
Results Reference
background
PubMed Identifier
3349581
Citation
Belhassen B, Glick A, Laniado S. Comparative clinical and electrophysiologic effects of adenosine triphosphate and verapamil on paroxysmal reciprocating junctional tachycardia. Circulation. 1988 Apr;77(4):795-805. doi: 10.1161/01.cir.77.4.795.
Results Reference
background
PubMed Identifier
6291805
Citation
Klein HO, Ninio R, Oren V, Lang R, Sareli P, DiSegni E, David D, Guerrero J, Kaplinsky E. The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment by equilibrium-gated radionuclide ventriculography. Circulation. 1983 Jan;67(1):101-10. doi: 10.1161/01.cir.67.1.101.
Results Reference
background
PubMed Identifier
6847809
Citation
Betriu A, Chaitman BR, Bourassa MG, Brevers G, Scholl JM, Bruneau P, Gagne P, Chabot M. Beneficial effect of intravenous diltiazem in the acute management of paroxysmal supraventricular tachyarrhythmias. Circulation. 1983 Jan;67(1):88-94. doi: 10.1161/01.cir.67.1.88.
Results Reference
background
PubMed Identifier
6277182
Citation
Mitchell LB, Schroeder JS, Mason JW. Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review. Am J Cardiol. 1982 Feb 18;49(3):629-35. doi: 10.1016/s0002-9149(82)80022-2.
Results Reference
background
PubMed Identifier
7051136
Citation
Singh BN, Hecht HS, Nademanee K, Chew CY. Electrophysiologic and hemodynamic effects of slow-channel blocking drugs. Prog Cardiovasc Dis. 1982 Sep-Oct;25(2):103-32. doi: 10.1016/0033-0620(82)90023-8. No abstract available.
Results Reference
background
PubMed Identifier
7471362
Citation
Kawai C, Konishi T, Matsuyama E, Okazaki H. Comparative effects of three calcium antagonists, diltiazem, verapamil and nifedipine, on the sinoatrial and atrioventricular nodes. Experimental and clinical studies. Circulation. 1981 May;63(5):1035-42. doi: 10.1161/01.cir.63.5.1035.
Results Reference
background
PubMed Identifier
6270785
Citation
Henderson AH, Lewis MJ. Basic mechanisms of 'calcium antagonists' (slow channel blockers). Scott Med J. 1981 Apr;26(2):156-60. doi: 10.1177/003693308102600215. No abstract available.
Results Reference
background
PubMed Identifier
6270786
Citation
Russell DC. Electrophysiology and antiarrhythmic effects of calcium antagonists. Scott Med J. 1981 Apr;26(2):161-4. doi: 10.1177/003693308102600216. No abstract available.
Results Reference
background
PubMed Identifier
7212475
Citation
Sung RJ, Elser B, McAllister RG Jr. Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med. 1980 Nov;93(5):682-9. doi: 10.7326/0003-4819-93-5-682.
Results Reference
background
PubMed Identifier
7445655
Citation
Seipel L, Breithardt G, Abendroth RR, Wiebringhaus E. [The electrophysiological effects of the Ca-antagonists gallopamil (D 600), dimeditiapramine (Ro 11-1781) and verapamil in man (author's transl)]. Z Kardiol. 1980 Aug;69(8):551-5. German.
Results Reference
background
PubMed Identifier
333889
Citation
Singh BN, Roche AH. Effects of intravenous verapamil on hemodynamics in patients with heart disease. Am Heart J. 1977 Nov;94(5):593-9. doi: 10.1016/s0002-8703(77)80128-2.
Results Reference
background
PubMed Identifier
1163442
Citation
Heng MK, Singh BN, Roche AH, Norris RM, Mercer CJ. Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. Am Heart J. 1975 Oct;90(4):487-98. doi: 10.1016/0002-8703(75)90431-7.
Results Reference
background
PubMed Identifier
5015294
Citation
Schamroth L, Krikler DM, Garrett C. Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J. 1972 Mar 11;1(5801):660-2. doi: 10.1136/bmj.1.5801.660.
Results Reference
background

Learn more about this trial

Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT

We'll reach out to this number within 24 hrs